Nicotinamide riboside ( DrugBank: Nicotinamide, Nicotinamide riboside )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1
6パーキンソン病2
18脊髄小脳変性症(多系統萎縮症を除く。)1
191ウェルナー症候群1

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 623 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04562831
(ClinicalTrials.gov)
October 7, 202010/9/2020The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS StudyAmyotrophic Lateral SclerosisDietary Supplement: EH301 (Nicotinamide Riboside/Pterostilbene)Haukeland University HospitalElysium HealthRecruiting35 YearsN/AAll380N/ANorway

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03568968
(ClinicalTrials.gov)
May 15, 202014/6/2018A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's DiseaseA Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK StudyParkinson DiseaseDietary Supplement: Nicotinamide Riboside;Drug: PlaceboHaukeland University HospitalNULLRecruiting18 YearsN/AAll400N/ANorway
2NCT03816020
(ClinicalTrials.gov)
March 9, 20197/12/2018NAD-supplementation in Drug naïve Parkinson's DiseaseNAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's DiseaseParkinson Disease;Neurodegenerative DiseasesDietary Supplement: Nicotinamide Riboside;Other: PlaceboHaukeland University HospitalNULLCompleted18 YearsN/AAll30N/ANorway

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04192136
(ClinicalTrials.gov)
September 3, 20206/12/2019NAD+ and Exercise in FANAD+ Precursor Supplementation With Exercise Training to Increase Aerobic Capacity in Friedreich's AtaxiaFriedreich Ataxia 1Dietary Supplement: Nicotinamide Riboside;Dietary Supplement: Placebo;Other: Exercise InterventionChildren's Hospital of PhiladelphiaNational Institutes of Health (NIH)Recruiting10 Years40 YearsAll72N/AUnited States

191. ウェルナー症候群


臨床試験数 : 3 薬物数 : 4 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs031190141
19/03/202127/11/2019Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndromeProspective, single-center, cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome - EMPOWER Werner syndrome
Werner syndrome;C16.320.925 / C18.452.284.960
Subjects ingest oral capsules of NR (nicotinamide riboside) once daily (total daily dose: nicotinamide riboside 1000 mg).Yokote KoutaroNULLRecruiting>= 20age oldNot applicableBoth30Phase 1-2Japan